Why is Abbott Laboratories stock rising today?

Abbott Laboratories stock experienced a 1.2% increase in mid-day trading following the company's agreement with the U.S. Department of Justice, concluding False Claims Act allegations related to powdered infant formula. The settlement totaled $385 million, with approximately $348.7 million going to the federal government and $36.3 million allocated to specific states for Medicaid-related claims.

Notably, the agreement did not involve a finding of fault or liability on Abbott's part, a significant factor that investors interpreted as a clean resolution rather than an admission of wrongdoing. This legal overhang, a persistent drag on sentiment toward the stock, has now been lifted. With this liability now quantified and largely behind the company, the market has begun to reprice shares to reflect a clearer path forward, particularly as Abbott approaches its next earnings report scheduled for mid-October.

This company-specific catalyst stands in contrast to a generally weaker session for U.S. equities, with major indices such as the S&P 500, Dow Jones, and Nasdaq all seeing slight declines. Abbott's healthcare peers, including Medtronic and Boston Scientific, did not provide any notable support, highlighting that ABT's movement is entirely driven by its own news.

The resolution of the longstanding government investigation, coupled with the absence of any admission of liability, provided investors with a concrete reason to bid up shares even amidst weak market conditions, with ABT reaching an intraday high of $104.44 before settling into its current trading range.